The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (hcc)

Oncologist

Volumn 16, Issue 12, 2011, Pages 1721-1728

  Wong, Hilda ^a   Tang, Yuen Fong ^b   Yao, TZY Jyun ^b   Chiu, Joanne ^a   Leung, Roland ^a   Chan, Pierre ^b,d   Cheung, Tan To ^a   Chan, Albert C ^a   Pang, Roberta W ^a,b   Poon, Ronnie ^a,b,c   Fan, SHEUNG Tat ^a,b,c   Yau, Thomas ^a,b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

^d RUTTONJEE HOSPITAL   (Hong Kong)

Author keywords

Advanced hcc; Elderly; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGE; AGED; ANEMIA; ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84855175227     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0192     Document Type: Article

References (46)

1. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. International Agency for Research on Cancer, World Health Organization, 2010. Available at http://globocan.iarc.fr, accessed June 3, 2011.
2. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Cho SJ, Yoon JH, Hwang SS et al. Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol 2007;22: 1226-1231.
4. Chiaramonte M, Stroffolini T, Vian A et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-2137.
5. Repetto L, Venturino A, Fratino L et al. Geriatric oncology: A clinical approach to the older patient with cancer. Eur J Cancer 2003;39:870-880.
6. Fentiman IS, Tirelli U, Monfardini S et al. Cancer in the elderly: Why so badly treated? Lancet 1990;335:1020-1022.
7. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. NEngl J Med 1999; 341:2061-2067.
8. Unger JM, Coltman CA Jr, Crowley JJ et al. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 2006;24:141-144.
9. Collier JD, Curless R, Bassendine MF et al. Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing 1994;23:22-27.
10. Giannini E, Romagnoli P, Fasoli A et al. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. Age Ageing 2002;31:457-462.
11. Dohmen K, Shirahama M, ShigematsuHet al. Optimal treatment strategy for elderly patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:859-865.
12. Poon RT, Fan ST, Lo CM et al. Hepatocellular carcinoma in the elderly: Results of surgical and nonsurgical management. Am J Gastroenterol 1999;94:2460-2466.
13. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-Hepatobiliary Cancers, Version 1. 2011. Available at http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf, accessed June 3, 2011.
14. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
16. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol 1972;34:187-220.
17. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
18. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley, 1980:1-439.
19. Hainsworth JD, Burris HA 3rd, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500-3505.
20. Del Mastro L, Perrone F, Repetto L et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005;16:253-258.
21. Feher O, Vodvarka P, Jassem J et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase III study. Ann Oncol 2005;16:899-908.
22. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2161.
23. Vogel C, O'Rourke M, Winer E et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999;10:397-402.
24. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
25. Ricci S, Antonuzzo A, Galli L et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study. Lung Cancer 2000;27:75-80.
26. Martoni A, Di Fabio F, Guaraldi M et al. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV nonsmall-cell lung cancer. Am J Clin Oncol 2001;24: 614-617.
27. Gridelli C, Cigolari S, Gallo C et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001;31:277-284.
28. Nakamura Y, Sekine I, Furuse K et al. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol 2000; 46:114-118.
29. Sandler A, Gray R, Perry MC et al. Paclitaxelcarboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
30. Ebi N, Semba H, Tokunaga SJ et al. A phase II trial of gefitinib monotherapy in chemotherapynaive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008;3: 1166-1171.
31. Wheatley-Price P, Ding K, Seymour L et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:2350-2357.
32. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naive patients _ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-766.
33. Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: Subset analysis from a randomized trial. J Natl Cancer Inst 2008;100:1454-1463.
34. Lenfant C, Chobanian AV, Jones DW et al. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): Resetting the hypertension sails. Hypertension 2003;41:1178-1179.
35. Maitland ML, Kasza KE, Karrison T et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15:6250-6257.
36. Nichols WW, Nicolini FA, Pepine CJ. Determinants of isolated systolic hypertension in the elderly. J Hypertens Suppl 1992;10:S73-S77.
37. Franklin SS, Gustin W 4th, Wong ND et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:308-315.
38. Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: Toxicity or target? Clin Cancer Res 2009;15:5947-5949.
39. Boehm S, Rothermundt C, Hess D et al. Antiangiogenic drugs in oncology: A focus on drug safety and the elderly-a mini-review. Gerontology 2010;56:303-309.
40. Spencer FA, Gore JM, Lessard D et al. Venous thromboembolism in the elderly.Acommunity-based perspective. Thromb Haemost 2008;100:780-788.
41. Qi Y, Dy GK, Nelson D et al. Incidence of bleeding and thrombosis among elderly patients (pts) undergoing systemic chemotherapy in advanced non-small cell lung cancer (NSCLC): An analysis of North Central Cancer Treatment Group (NCCTG) trials. J Clin Oncol 2010;28(15 suppl): e18093.
42. Pili R, Guo Y, Chang J et al. Altered angiogenesis underlying age-dependent changes in tumor growth. J Natl Cancer Inst 1994;86:1303-1314.
43. Kaptzan T, Skutelsky E, Itzhaki O et al. Efficacy of anti-angiogenic treatment of tumors in old versus young mice. Mech Ageing Dev 2006;127: 398-409.
44. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10: 25-34.
45. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
46. Basso U, Monfardini S. Multidimensional geriatric evaluation in elderly cancer patients: A practical approach. Eur J Cancer Care (Engl) 2004;13: 424-433.